Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab (STAMP) Trial
September 22, 2020
The STAMP trial is currently recruiting participants at sites all across the country.
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
For more information, click here.
The authoritative source on Merkel cell carcinoma.
Last updated:
September 13, 2023
About the Disease
- What is a Merkel cell?
- What is Merkel cell carcinoma?
- Symptoms & appearance of Merkel cell carcinoma
- Causes of Merkel cell carcinoma
Testing & Diagnosis
Created in partnership with:
Seattle Multidisciplinary MCC Team, University of Washington MCC Research, and Fred Hutchinson Cancer Center.